Heart Failure: Seven-Market Drug Forecast and Market Analysis - Update

1.1 The HF market will exhibit strong growth between 2022 and 2032
1.2 Label expansions of CV drugs will fuel market growth
1.3 Unmet needs remain in the HF market despite the availability of well-established therapies
1.4 Injectable agents will dominate the HF market
1.5 What do physicians think?

2.1 Catalyst
2.2 Related reports

3.1 Etiology and pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Biomarkers/targets of interest
3.2 Classification or staging systems
3.3 Prognosis

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology
4.4.1 Sources
4.4.2 Forecast assumptions and methods
4.4.3 Forecast assumptions and methods: diagnosed incident cases of HF - 7MM
4.4.4 Forecast assumptions and methods: diagnosed incident cases of HF by ejection fraction
4.4.5 Forecast assumptions and methods: hospitalizations for acute HF
4.4.6 Forecast assumptions and methods: acute HF hospitalizations based on presentation
4.4.7 Forecast assumptions and methods: hospital length of stay days for acute HF hospitalizations
4.4.8 Forecast assumptions and methods: re-admissions within 30 days post-discharge after acute HF hospitalization
4.4.9 Forecast assumptions and methods: diagnosed prevalent cases of HF - 7MM
4.4.10 Forecast assumptions and methods: diagnosed prevalent cases of HF by ejection fraction
4.4.11 Forecast assumptions and methods: diagnosed prevalent cases of HF by New York Heart Association classes
4.4.12 Forecast assumptions and methods: diagnosed prevalent cases of HF with preserved ejection fraction (left ventricular ejection fraction =50%) by New York Heart Association class
4.4.13 Forecast assumptions and methods: diagnosed prevalent cases of HF with mid-range ejection fraction (left ventricular ejection fraction 40-49%) by New York Heart Association class
4.4.14 Forecast assumptions and methods: diagnosed prevalent cases of HF with reduced ejection fraction (left ventricular ejection fraction < 40%) by New York Heart Association class
4.4.15 Forecast assumptions and methods: diagnosed prevalent cases of HF by American College of Cardiology Foundation/American Heart Association stages
4.5 Epidemiological forecast for HF (2022-32)
4.5.1 Diagnosed incident cases of HF
4.5.2 Age-specific diagnosed incident cases of HF
4.5.3 Sex-specific diagnosed incident cases of HF
4.5.4 Diagnosed incident cases of HF by ejection fraction
4.5.5 Hospitalizations for acute HF
4.5.6 Acute HF hospitalizations based on presentation
4.5.7 Hospital length of stay for acute HF
4.5.8 Re-admissions within 30 days post-discharge after acute HF
4.5.9 Diagnosed prevalent cases of HF
4.5.10 Age-specific diagnosed prevalent cases of HF
4.5.11 Sex-specific diagnosed prevalent cases of HF
4.5.12 Diagnosed prevalent cases of HF by ejection fraction
4.5.13 Diagnosed prevalent cases of HF by New York Heart Association class
4.5.14 Diagnosed prevalent cases of HF with preserved ejection fraction (left ventricle ejection fraction =50%) by New York Heart Association class
4.5.15 Diagnosed prevalent cases of HF with mid-range ejection fraction (left ventricle ejection fraction 40-49%) by New York Heart Association class
4.5.16 Diagnosed prevalent cases of HF with reduced ejection fraction (left ventricle ejection fraction < 40%) by New York Heart Association class
4.5.17 Diagnosed prevalent cases of HF by American College of Cardiology Foundation/American Heart Association stages
4.6 Discussion
4.6.1 Epidemiological forecast insight
4.6.2 COVID-19 impact
4.6.3 Limitations of the analysis
4.6.4 Strengths of the analysis

5.1 Diagnosis and treatment overview
5.2 KOL insights on disease management

6.1 Overview

7.1 Overview
7.2 Lack of therapies for HF with preserved ejection fraction patients
7.3 Lack of therapies for acute HF
7.4 Compliance and optimal management of HF treatments
7.5 Preventative therapies for patients at risk of developing HF

8.1 Overview
8.1.1 Label expansion for therapies approved for other indications
8.1.2 Mergers and acquisitions to expand the product pipeline
8.2 Clinical trials design
8.2.1 Clinical endpoints for HF
8.2.2 Inclusion and exclusion criteria

9.1 Overview
9.2 Promising drugs in clinical development

10.1 Overview
10.2 Competitive assessment

11.1 Overview
11.2 Deal-making trends

12.1 Global markets
12.1.1 Forecast
12.1.2 Drivers and barriers - global issues
12.2 US
12.2.1 Forecast
12.2.2 Key events
12.2.3 Drivers and barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key events
12.3.3 Drivers and barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key events
12.4.3 Drivers and barriers

13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.3.1 Forecasting methodology
13.4 Primary research - KOLs interviewed for this report
13.4.1 KOLs
13.5 Primary research - prescriber survey
13.6 About the authors
13.6.1 Analyst
13.6.2 Therapy Area Director
13.6.3 Epidemiologist
13.6.4 Vice President of Disease Intelligence and Epidemiology
13.6.5 Global Head of Pharma Research, Analysis, and Competitive Intelligence

• Contact the Publisher

Table 1: Heart failure: key metrics in the 7MM
Table 2: Types of chronic HF
Table 3: Causes of HF
Table 4: Compensatory mechanisms in HF patients
Table 5: Symptoms of HF
Table 6: Types of chronic HF
Table 7: Comparison of two HF classification systems
Table 8: Risk factors and comorbidities for HF
Table 9: Treatment guidelines for HF
Table 10: Top 10 deals by value, 2019-24
Table 11: HF market - global drivers and barriers, 2022-32
Table 12: Key events impacting sales for HF in the US, 2022-32
Table 13: HF market - drivers and barriers in the US, 2022-32
Table 14: Key events impacting sales for HF in the 5EU, 2022-32
Table 15: HF market - drivers and barriers in the 5EU, 2022-32
Table 16: Key events impacting sales for HF in Japan, 2022-32
Table 17: HF market - drivers and barriers in Japan, 2022-32
Table 18: High-prescribing physicians (non-KOLs) surveyed, by country

Figure 1: Global sales forecast by country for HF in 2022 and 2032
Figure 2: Analysis of the company portfolio gap in HF during the forecast period
Figure 3: Competitive assessment of the injectable late-stage pipeline agents that the analyst expects to be licensed for the treatment of HF during the forecast period
Figure 4: Competitive assessment of the oral late-stage pipeline agents that the analyst expects to be licensed for the treatment of HF during the forecast period
Figure 5: Changes in cardiac structure in HF
Figure 6: 7MM, diagnosed incidence of HF (cases per 100,000 population), men and women, all ages, 2022
Figure 7: 7MM, diagnosed prevalence of HF (%), men and women, all ages, 2022
Figure 8: 7MM, sources used and not used to forecast the diagnosed incident cases of HF
Figure 9: 7MM, sources used to forecast the diagnosed incident cases of HF by EF
Figure 10: 7MM, sources used to forecast the hospitalization for acute HF
Figure 11: 7MM, sources used to forecast the hospitalizations for acute HF by presentation
Figure 12: 7MM, sources used to forecast the hospital LoS for acute HF
Figure 13: 7MM, sources used to forecast the re-admissions within 30 days post-discharge after acute HF hospitalization
Figure 14: 7MM, sources used to forecast the diagnosed prevalent cases of HF
Figure 15: 7MM, sources used to forecast the diagnosed prevalent cases of HF by EF
Figure 16: 7MM, sources used to forecast the diagnosed prevalent cases of HF by NYHA class
Figure 17: 7MM, sources used to forecast the diagnosed prevalent cases of HF-PEF, HF-mrEF, and HF-REF by NYHA class
Figure 18: 7MM, sources used to forecast the diagnosed prevalent cases of HF by EF
Figure 19: 7MM, diagnosed incident cases of HF, N, both sexes, all ages, 2022
Figure 20: 7MM, diagnosed incident cases of HF by age, N, both sexes, 2022
Figure 21: 7MM, diagnosed incident cases of HF by sex, N, all ages, 2022
Figure 22: 7MM, diagnosed incident cases of HF by EF, N, both sexes, all ages, 2022
Figure 23: 7MM, hospitalizations for acute HF, N, both sexes, all ages, 2022
Figure 24: 7MM, acute HF hospitalizations based on presentation, N, both sexes, all ages, 2022
Figure 25: 7MM, hospital LoS for acute HF, days, both sexes, all ages, 2022
Figure 26: 7MM, re-admissions within 30 days post-discharge after acute HF hospitalization, N, both sexes, all ages, 2022
Figure 27: 7MM, diagnosed prevalent cases of HF, N, both sexes, all ages, 2022
Figure 28: 7MM, diagnosed prevalent cases of HF by age, N, both sexes, 2022
Figure 29: 7MM, diagnosed prevalent cases of HF by sex, N, all ages, 2022
Figure 30: 7MM, diagnosed prevalent cases of HF by sex, N, all ages, 2022
Figure 31: 7MM, diagnosed prevalent cases of HF by NYHA classes, N, both sexes, all ages, 2022
Figure 32: 7MM, diagnosed prevalent cases of HF-PEF (LVEF =50%) by NYHA class, N, both sexes, all ages, 2022
Figure 33: 7MM, diagnosed prevalent cases of HF-mrEF (LVEF = 40-49%) by NYHA class, N, both sexes, all ages, 2022
Figure 34: 7MM, diagnosed prevalent cases of HF-REF (LVEF < 40%) by NYHA class, N, both sexes, all ages, 2022
Figure 35: 7MM, diagnosed prevalent cases of HF by ACCF/AHA stages, N, both sexes, all ages, 2022
Figure 36: Diagnosis algorithm for chronic HF
Figure 37: Unmet needs and opportunities in chronic and acute HF
Figure 38: Overview of the development pipeline in HF
Figure 39: Key late-stage trials for the promising pipeline agents that the analyst expects be licensed for HF in the 7MM during the forecast period
Figure 40: Competitive assessment of the late-stage pipeline agents that the analyst expects to be licensed for the treatment of HF during the forecast period
Figure 41: Competitive assessment of the oral pipeline drugs benchmarked against the standard of care (SOC)
Figure 42: Competitive assessment of the injectable pipeline drugs benchmarked against the standard of care (SOC)
Figure 43: Analysis of the company portfolio gap in HF during the forecast period
Figure 44: Global (7MM) sales forecast by country for HF in 2022 and 2032
Figure 45: Sales forecast by class for HF in the US in 2022 and 2032
Figure 46: Sales forecast by class for HF in the 5EU in 2022 and 2032
Figure 47: Sales forecast by class for HF in Japan in 2022 and 2032